摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 3-chloro-2,4,5-trifluoro-6-methyl-β-oxobenzenepropanoate | 119915-66-1

中文名称
——
中文别名
——
英文名称
ethyl 3-chloro-2,4,5-trifluoro-6-methyl-β-oxobenzenepropanoate
英文别名
ethyl 2-(3-chloro-6-methyl-2,4,5-trifluorobenzoyl)acetate;ethyl 3-chloro-2,4,5-trifluoro-6-methylbenzoylacetate;ethyl 3-(3-chloro-2,4,5-trifluoro-6-methylphenyl)-3-oxopropanoate
ethyl 3-chloro-2,4,5-trifluoro-6-methyl-β-oxobenzenepropanoate化学式
CAS
119915-66-1
化学式
C12H10ClF3O3
mdl
——
分子量
294.658
InChiKey
JHGCBMAOBHBWTJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    19
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 3-chloro-2,4,5-trifluoro-6-methyl-β-oxobenzenepropanoate盐酸乙酸酐 、 sodium hydride 作用下, 以 乙醇 为溶剂, 生成 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid
    参考文献:
    名称:
    5-甲基-4-氧代喹啉羧酸的合成
    摘要:
    制备了一系列5-甲基-4-氧代-3-喹啉羧酸,其中八个位置被氟,氯,甲基或氢取代。这些喹诺酮是由衍生自恶唑啉8和16的合适的2-甲基-3,4,6-三氟苯甲酸合成的。恶唑啉部分既是邻位导向基团(在可行的情况下)又是保护基团;三甲基甲硅烷基部分被用来封闭分子中最酸性的位点。
    DOI:
    10.1002/jhet.5570270616
  • 作为产物:
    参考文献:
    名称:
    5-甲基-4-氧代喹啉羧酸的合成
    摘要:
    制备了一系列5-甲基-4-氧代-3-喹啉羧酸,其中八个位置被氟,氯,甲基或氢取代。这些喹诺酮是由衍生自恶唑啉8和16的合适的2-甲基-3,4,6-三氟苯甲酸合成的。恶唑啉部分既是邻位导向基团(在可行的情况下)又是保护基团;三甲基甲硅烷基部分被用来封闭分子中最酸性的位点。
    DOI:
    10.1002/jhet.5570270616
点击查看最新优质反应信息

文献信息

  • Pyridonecarboxylic acid derivatives or salts thereof and drugs
    申请人:Wakunaga Pharmaceutical Co., Ltd.
    公开号:US06136823A1
    公开(公告)日:2000-10-24
    The invention relates to pyridonecarboxylic acid derivatives represented by the general formula (1): ##STR1## wherein R.sup.1 is --OH, a carboxy-protecting group or (alkyl)amino group, R.sup.2 is H, or --NO.sub.2, (protected) amino, (protected) hydroxyl, lower alkyl or lower alkoxyl group, R.sup.3 is a halogen atom, H, or --NO.sub.2, lower alkyl, lower alkoxyl or amino group, R.sup.4 is an azido, (substituted) hydrazino, (substituted) amino, lower alkoxyl or hydroxyl group, R.sup.5, R.sup.6 and R.sup.7 are independently H, --NO.sub.2, halogen atom or lower alkyl group, R.sup.8 is a --NO.sub.2, (substituted) amino, --OH or lower alkoxyl group, A is N or C--R.sup.12, in which R.sup.12 is H, halogen atom, or (substituted) lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, lower alkylthio or nitro group, and B is N or C--R.sup.13, in which R.sup.13 is H or halogen atom, or salts thereof, and medicine comprising such a compound as an active ingredient. The derivatives or the salts thereof exhibit excellent antibacterial action and peroral absorbability, scarcely cause side effects, and are easy of synthesis.
    该发明涉及由通式(1)表示的吡啶酮羧酸衍生物:##STR1##其中R.sup.1为--OH、羧保护基团或(烷基)氨基团,R.sup.2为H或--NO.sub.2、(保护)氨基、(保护)羟基、较低烷基或较低烷氧基团,R.sup.3为卤素原子、H或--NO.sub.2、较低烷基、较低烷氧基或氨基团,R.sup.4为偶氮基、(取代)叠氮基、(取代)氨基、较低烷氧基或羟基团,R.sup.5、R.sup.6和R.sup.7独立地为H、--NO.sub.2、卤素原子或较低烷基团,R.sup.8为--NO.sub.2、(取代)氨基、--OH或较低烷氧基团,A为N或C--R.sup.12,其中R.sup.12为H、卤素原子或(取代)较低烷基、较低烯基、较低炔基、较低烷氧基、较低硫代烷基或硝基团,B为N或C--R.sup.13,其中R.sup.13为H或卤素原子,或其盐,以及包括此类化合物作为活性成分的药物。这些衍生物或其盐表现出优异的抗菌作用和口服吸收性,几乎不会引起副作用,并且易于合成。
  • NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF
    申请人:WAKUNAGA PHARMACEUTICAL CO., LTD.
    公开号:US20190276407A1
    公开(公告)日:2019-09-12
    A pyridonecarboxylic acid derivative or a salt thereof is represented by Formula (1), where R 1 is hydrogen, a halogen atom, a lower alkyl group, or an amino group; R 2 is —NH—R 6 , where R 6 is hydrogen, a lower alkyl group, an amino lower alkyl group, or the like; —O—R 7 , where R 7 is hydrogen, a lower alkyl group, or the like; —(CH 2 ) m —R 8 , where R 8 is an amino group or the like, m is 1, 2, 3 or 4; or a cyclic amino group of Formula (2), where Y represents NH or C—R 9a R 9b , where R 9a and R 9b are each independently hydrogen, a lower alkyl group, an amino group, a lower alkyl amino group, or the like; n and p are 1 or 2; R 3 is hydrogen, a halogen atom, a lower alkyl group, or the like; R 4 is hydrogen or a carboxyl group-protecting group; and R 5 is hydrogen or a hydroxyl group-protecting group.
    化合物或其盐可由以下式(1)表示,其中R1是氢、卤素原子、低烷基或氨基;R2是—NH—R6,其中R6是氢、低烷基、氨基低烷基或类似物;—O—R7,其中R7是氢、低烷基或类似物;—(CH2)m—R8,其中R8是氨基或类似物,m为1、2、3或4;或由以下式(2)的环状氨基团表示,其中Y代表NH或C—R9aR9b,其中R9a和R9b各自独立地是氢、低烷基、氨基、低烷基氨基或类似物;n和p为1或2;R3是氢、卤素原子、低烷基或类似物;R4是氢或羧基保护基团;R5是氢或羟基保护基团。
  • Benzoheterocyclic compounds
    申请人:Otsuka Pharmaceutical Company, Limited
    公开号:US05591744A1
    公开(公告)日:1997-01-07
    Novel 4-oxoquinoline-3-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 is cyclopropyl which may have 1 to 3 substituents of alkyl and halogen; phenyl which may be substituted by 1 to 3 substituents of alkoxy, halogen and OH; alkyl which may be substituted by halogen, alkanoyloxy or OH; alkenyl; or thienyl, R.sup.2 is 5- to 9-membered saturated or unsaturated heterocyclic ring which may be sustituted, R.sup.3 is alkyl or halogen, R.sup.4 is alkyl or halogen, R is H or alkyl, R.sup.1 and R.sup.3 may be taken together to form ##STR2## wherein R.sup.31 is H or alkyl, and X is halogen, provided that R.sup.3 and R.sup.4 are not simultaneously halogen, and salts thereof, said compounds having excellent antimicrobial activity and hence being useful as an antimicrobial agent, and a pharmaceutical composition containing said compound as an active ingredient.
    化合物的名称为4-氧喹啉-3-羧酸,其化学式为:##STR1## 其中,R1为环丙基,可以有1到3个烷基和卤素取代基;苯基,可以被1到3个烷氧基,卤素和羟基取代;烷基,可以被卤素,烷酰氧基或羟基取代;烯基;或噻吩基,R2为5到9个成员的饱和或不饱和杂环,可以被取代,R3为烷基或卤素,R4为烷基或卤素,R为氢或烷基,R1和R3可以一起取代形成##STR2## 其中,R31为氢或烷基,X为卤素,前提是R3和R4不能同时为卤素。这些化合物具有优异的抗微生物活性,因此可用作抗微生物剂,并且含有该化合物作为活性成分的制药组合物。
  • NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
    申请人:WAKUNAGA PHARMACEUTICAL CO., LTD.
    公开号:EP0945435A1
    公开(公告)日:1999-09-29
    The invention relates to pyridonecarboxylic acid derivatives represented by the general formula (1): wherein R1 is -OH, a carboxy-protecting group or (alkyl)-amino group, R2 is H, or -NO2, (protected) amino, (protected) hydroxyl, lower alkyl or lower alkoxyl group, R3 is a halogen atom, H, or -NO2, lower alkyl, lower alkoxyl or amino group, R4 is an azido, (substituted) hydrazino, (substituted) amino, lower alkoxyl or hydroxyl group, R5, R6 and R7 are independently H, -NO2, halogen atom or lower alkyl group, R8 is a -NO2, (substituted) amino, -OH or lower alkoxyl group, A is N or C-R12, in which R12 is H, halogen atom, or (substituted) lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, lower alkylthio or nitro group, and B is N or C-R13, in which R13 is H or halogen atom, or salts thereof, and medicine comprising such a compound as an active ingredient. The derivatives or the salts thereof exhibit excellent antibacterial action and peroral absorbability, scarcely cause side effects, and are easy of synthesis.
    本发明涉及通式(1)所代表的吡啶甲酸衍生物: 其中 R1 是-OH、羧基保护基团或(烷基)-氨基;R2 是 H、或-NO2、(保护)氨基、(保护)羟基、低级烷基或低级烷氧基;R3 是卤素原子、H、或-NO2、低级烷基、低级烷氧基或氨基;R4 是叠氮基、(取代的)肼基、(取代的)氨基、低级烷氧基或羟基;R5、R6 和 R7 独立地是 H、-NO2、A是N或C-R12,其中R12是H、卤素原子或(取代的)低级烷基、低级烯基、低级炔基、低级烷氧基、低级烷硫基或硝基,B是N或C-R13,其中R13是H或卤素原子,或其盐,以及包含此类化合物作为活性成分的药物。这些衍生物或其盐具有出色的抗菌作用和口腔吸收性,几乎不会产生副作用,而且易于合成。
  • 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP0287951B1
    公开(公告)日:1996-07-03
查看更多